<code id='927BA1EC7F'></code><style id='927BA1EC7F'></style>
    • <acronym id='927BA1EC7F'></acronym>
      <center id='927BA1EC7F'><center id='927BA1EC7F'><tfoot id='927BA1EC7F'></tfoot></center><abbr id='927BA1EC7F'><dir id='927BA1EC7F'><tfoot id='927BA1EC7F'></tfoot><noframes id='927BA1EC7F'>

    • <optgroup id='927BA1EC7F'><strike id='927BA1EC7F'><sup id='927BA1EC7F'></sup></strike><code id='927BA1EC7F'></code></optgroup>
        1. <b id='927BA1EC7F'><label id='927BA1EC7F'><select id='927BA1EC7F'><dt id='927BA1EC7F'><span id='927BA1EC7F'></span></dt></select></label></b><u id='927BA1EC7F'></u>
          <i id='927BA1EC7F'><strike id='927BA1EC7F'><tt id='927BA1EC7F'><pre id='927BA1EC7F'></pre></tt></strike></i>

          Home / fashion / leisure time

          leisure time


          leisure time

          author:explore    Page View:9317
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In